作者:Nane Griem‐Krey、Bente Frølund、Aleš Marek、Petrine Wellendorph
DOI:10.1002/jlcr.3870
日期:2021.2
GHB (γ-hydroxybutyrate) is not only an endogenously present small molecule but also a clinically prescribed drug for the symptomatic treatment of narcolepsy. However, GHB's mechanism of action remains to be uncovered. Within the CNS, GHB targets both GABAB receptors and a pharmacologically distinct population of high-affinity binding sites with unknown molecular identity. HOCPCA (3-hydroxycyclopent-1-enecarboxylic acid) is a structural analog of GHB selectively targeting GHB high-affinity binding sites. Here, we discuss the usefulness of 3H- and 11C-labeled HOCPCA as radioligands for selectively probing GHB high-affinity binding sites and their application in drug discovery. As such, [3H]HOCPCA's exceptional affinity and selectivity makes it an indispensable tool in drug discovery, and its utility has been demonstrated in, for example, homogenate binding studies, in vitro as well as ex vivo autoradiography. Moreover, the successful synthesis of [11C]HOCPCA is a starting point for further ligand development for future in vivo investigations of GHB high-affinity binding sites.
GHB(γ-羟基丁酸)不仅是一种内源性的小分子,也是一种临床上用于治疗嗜睡症状的处方药。然而,GHB的作用机制仍未被揭示。在中枢神经系统中,GHB既作用于GABAB受体,也作用于一群药理学上不同的高亲和力结合位点,这些位点的分子身份尚未明确。HOCPCA(3-羟基环戊-1-烯羧酸)是GHB的结构类似物,特异性地作用于GHB的高亲和力结合位点。本文讨论了3H和11C标记的HOCPCA作为放射性配体,用于特异性地探测GHB高亲和力结合位点的效用,以及它们在药物发现中的应用。因此,[3H]HOCPCA的卓越亲和力和选择性使其成为药物发现中不可或缺的工具,其效用已在匀浆结合研究、体外及离体放射自显影中得到证明。此外,[11C]HOCPCA的成功合成是一个起点,为未来开发用于研究GHB高亲和力结合位点的配体提供了可能。